76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Savara Inc
Closed
SectorHealthcare
2.22 0.91
Overview
Share price change
24h
Min
2.14
Max
2.22
Income | 2.4M -27M |
|---|---|
EPS | -0.12 |
Profit margin | -10,677.941 |
Employees | 59 |
EBITDA | 2.7M -28M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +215.35% upside |
Next Earnings | 8 Aug 2025 |
|---|
Market Cap | -148M 373M |
|---|---|
Previous open | 1.31 |
Previous close | 2.22 |
Technical Score
By Trading Central
Confidence
Neutral Evidence
Savara Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Savara Inc Forecast
Price Target
By TipRanks
215.35% upside
12 Months Forecast
Average 7.19 USD 215.35%
High 16 USD
Low 2 USD
Based on 8 Wall Street analysts offering 12 month price targets forSavara Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
